Aquestive Therapeutics (AQST) PT Lowered to $10 at JMP Securities
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rises after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts AQST Hot Sheet
Price: $3.88 --0%
Rating Summary:
12 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Rating Summary:
12 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Join SI Premium – FREE
JMP Securities analyst Jason Butler lowered the price target on Aquestive Therapeutics (NASDAQ: AQST) to $10.00 (from $17.00) while maintaining a Market Outperform rating.
You May Also Be Interested In
- Aquestive Therapeutics Inc. (AQST) Misses Q3 EPS by 6c
- United Therapeutics Corp. (UTHR) PT Raised to $720 at Raymond James
- Insulet Corporation (PODD) PT Raised to $163 at TD Cowen
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
